Progenics Pharmaceuticals Earnings: Here’s Why the Stock is Rising Now

Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) had a loss and beat Wall Street’s expectations, AND beat the revenue expectation. The revenue beat is a positive sign to shareholders seeking high growth out of the company.

Progenics Pharmaceuticals Inc. Earnings Cheat Sheet

Results: Adjusted Earnings Per Share increased to $-0.01 in the quarter versus EPS of $-0.32 in the year-earlier quarter.

Revenue: Rose 303.64% to $8.88 million from the year-earlier quarter.

Actual vs. Wall St. Expectations: Progenics Pharmaceuticals Inc. reported adjusted EPS loss of $0.01 per share. By that measure, the company beat the mean analyst estimate of $-0.31. It beat the average revenue estimate of $1.16 million.

Quoting Management: There was no comment from management.

Key Stats (on next page)…